Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
23andMe reported first-quarter revenue that missed expectations, days after rejecting CEO Anne Wojcicki’s offer to take the struggling DNA-testing firm private https://t.co/GmbkmVBocU via @business
23andMe Fiscal Q1 Revenues Fall 34 Percent; Firm Shutters Therapeutics Discovery Business https://t.co/gHmTBTejVo
Ginkgo Bioworks Reports Second Quarter 2024 Financial Results $DNA https://t.co/P3GxOOsU6O
23andMe reported a significant decline in its first-quarter fiscal 2025 revenue, falling 34 percent, which missed market expectations. This announcement comes shortly after the company rejected an offer from CEO Anne Wojcicki to take the struggling DNA-testing firm private. In addition to the financial challenges, 23andMe has decided to shutter its therapeutics discovery business.
